Memphasys Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MEM.AX research report →
Price Chart
About the company
Memphasys Limited, an Australian enterprise, is dedicated to the development, manufacturing, and distribution of advanced cell and protein separation technologies, alongside associated consumable goods, for the healthcare, veterinary, and biotechnology sectors. Its leading innovation is Felix, an automated device engineered to swiftly and gently isolate high-quality sperm from raw semen samples, primarily for use in human in vitro fertilization (IVF) procedures. The company's product portfolio also includes ROSA, a rapid oxidative stress assay; the Samson Device, designed for quick equine pregnancy prediction; SemPort, a system for central laboratory human semen analysis from geographically dispersed donors; and AI-Port, an ambient temperature semen transport solution for animal artificial insemination.
- CEO
- R. John Aitken
- IPO
- 2007
- Employees
- 24
- HQ
- Homebush, NSW, AU
Get TickerSpark's AI analysis on MEM.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $18.52M
- P/E
- -2.86
- PEG
- -0.03
- P/S
- 86.56
- P/B
- 3.17
- EV/EBITDA
- -8.14
- Div Yield
- 0.00%
- Gross Margin
- -375.99%
- Op Margin
- -1664.02%
- Net Margin
- -2015.96%
- ROE
- -91.88%
- ROIC
- -42.41%
Latest fiscal year · YoY change
- Revenue
- $526.92K+778.2%
- Gross Profit
- $431.06K+127.5%
- Op Income
- $-2,565,515
- Net Income
- $-4,941,913-11.3%
- EPS
- $-0.00+21.1%
- OCF Growth
- +25.4%
- FCF Growth
- +37.7%
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- 0.49
- RSI (14)
- 41
- Avg Volume
- 3.38M
No earnings-call transcripts are available for MEM.AX yet.
- Free Float
- 44.7%
- Shares Outstanding
- 3.09B
- Float Shares
- 1.38B
Our MEM.AX coverage
Recent articles, reports, and earnings notes.
No research on MEM.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MEM.AX report →Memphasys signs national supply agreement with Monash IVF for Felix sperm selection system
proactiveinvestors.com · Jun 16
FTSE 100 Live: Stocks called higher as Trump words on Israel help oil retreat
proactiveinvestors.com · Jun 2
Anthropic confidentially files to go public in the US
proactiveinvestors.com · Jun 1
Memphasys secures first South-East Asian commercialisation agreement for Felix™
proactiveinvestors.com · Jun 1
Small Cap Watch: commercial expansion updates drive news flow
proactiveinvestors.com · Jun 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.